Table 4 Post-treatment according to EGFR mutation status as second line between Del-19and L858R (n = 78)
| Post-treatment | Del-19 (n = 36) | L858R (n = 42) | ||
|---|---|---|---|---|
| No.of patients | % | No.of patients | % | |
| Not received | 0 | 0% | 0 | 0% |
| Received | ||||
| Platinum doublet therapy | 0 | 0% | 0 | 0% |
| Single-agent chemotherapy | 1 | 2.8% | 1 | 2.4% |
| EGFR-TKI therapy | 32 | 88.9% | 38 | 90.5% |
| Other molecular target drug therapy | 2 | 5.5% | 2 | 4.7% |
| Immunotherapy | 0 | 0% | 0 | 0% |
| Other | 1 | 2.8% | 0 | 0% |
| During first line chemotherapy | 0 | 0% | 1 | 2.4% |
